Machine Learning Scientist II/Sr (Biomedical Images)

United States

Apply with AI Apply

$152,000 – $215,000Compensation

Junior (1 to 2 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, Medical Imaging, Biomedical EngineeringIndustries

Requirements

Candidates should possess a PhD with 3+ years of industry experience or an MS with 5+ years of industry experience in Computer Vision, Machine Learning, Biomedical Engineering, or a related field. They must have solid experience with deep learning for images, including self-supervised pre-training, Vision Transformers, or vector quantization methods, along with proficiency in PyTorch or JAX and experience running distributed training on GPUs or cloud HPC resources. Strong software engineering practices, including version control, testing, continuous integration, code review, and containerization, are also required.

Responsibilities

The Machine Learning Scientist II or Senior will evaluate, adapt, and integrate pre-trained computer-vision models into Enchant's existing modalities, locate and curate clinical imaging datasets and establish benchmarks for model performance, build reliable data pipelines for large image collections, convert research prototypes into production services on multi-GPU/HPC infrastructure, collaborate with discovery, pre-clinical, and clinical teams to translate image insights into experimental and trial strategies, and share results through code, documentation, and internal presentations; they will also mentor colleagues in vision and multimodal ML.

Skills

Computer Vision

Deep Learning

Vision Transformers

Vector Quantization

PyTorch

JAX

Distributed GPU Training

Medical Imaging

Data Pipelines

Model Deployment

Multimodal ML

Axsome Therapeutics Inc

Develops therapies for CNS disorders

About Axsome Therapeutics Inc

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

New York City, New YorkHeadquarters

2012Year Founded

$430.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees